Suppr超能文献

钕钇铝石榴石激光与硬化疗法治疗腿部毛细血管扩张症的对比研究。

Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy.

作者信息

Ianosi Gabriel, Ianosi Simona, Calbureanu-Popescu Madalina Xenia, Tutunaru Cristina, Calina Daniela, Neagoe Daniela

机构信息

Department of Surgery, Medical Center Dr. Ianosi, University of Medicine and Pharmacy of Craiova, 200000 Craiova, Romania.

Department of Dermatology, Medical Center Dr. Ianosi, University of Medicine and Pharmacy of Craiova, 200000 Craiova, Romania.

出版信息

Exp Ther Med. 2019 Feb;17(2):1106-1112. doi: 10.3892/etm.2018.6985. Epub 2018 Nov 16.

Abstract

Telangiectasias and reticular veins of the lower extremities are common lesions. Sclerotherapy is considered the gold standard for treatment. The aim of our prospective randomized study was to compare the efficacy and safety of hypertonic 20% saline/2% lignocaine (HS) versus polidocanol 0.5% (POL) versus long-pulsed neodymium:ytrium aluminium garnet (Nd:YAG) laser (LAS) treatments of leg telangiectasias in women, using each patient as her own control. We included in this study 285 women with primary leg telangiectasias and reticular veins (CEAP) in order to be treated with sclerotherapy or laser. One leg was treated with either LAS, POL or HS. The other leg received, randomly, one other of these treatments. At the end there were 190 legs treated with each method. There were two sessions at 8-week interval. Assessment of vessel clearing and complications was conducted 2 months after each session using before and after photographs of the leg vessels using a six-point scale from 0 (no change) to 5 (100% cleared). For telangiectasias under 1 mm diameter LAS was better (RR=9.72, P<0.0001) than HS and also POL was better (RR=2.70, P=0.003); for telangiectasias over 1 mm diameter LAS and POL were better too (RR=2.70, P=0.003) respectively (RR=1.44, P=0.00756). For telangiectasias under 1 mm LAS treatment is clearly superior to POL treatment. For telangiectasias over 1 mm the hazard regression model showed a hazard ratio of 3.97 (P=0.047) for LAS and 4.96 (P=0.486) for POL vs. HS treatment. In conclusion, telangiectasias and reticular veins of the lower extremities can be successfully treated with Nd:YAG laser or sclerotherapy. Nd:YAG laser is recommended in treating small telangiectasias (under 1 mm diameter) while sclerotherapy with polidocanol is more efficient as long as telangiectasias diameter is growing.

摘要

下肢毛细血管扩张和网状静脉是常见的病变。硬化疗法被认为是治疗的金标准。我们这项前瞻性随机研究的目的是,以每位患者自身作为对照,比较20%高渗盐水/2%利多卡因(HS)、0.5%聚多卡醇(POL)和长脉冲钕:钇铝石榴石(Nd:YAG)激光(LAS)治疗女性腿部毛细血管扩张的疗效和安全性。我们纳入了285例患有原发性腿部毛细血管扩张和网状静脉(CEAP)的女性,以便接受硬化疗法或激光治疗。一条腿用LAS、POL或HS进行治疗。另一条腿随机接受另外一种治疗。最后,每种方法治疗了190条腿。每隔8周进行两个疗程。在每个疗程后2个月,使用腿部血管治疗前后的照片,采用从0(无变化)到5(100%清除)的六点量表对血管清除情况和并发症进行评估。对于直径小于1mm的毛细血管扩张,LAS优于HS(RR = 9.72,P < 0.0001),POL也优于HS(RR = 2.70,P = 0.003);对于直径大于1mm的毛细血管扩张,LAS和POL也分别更优(RR = 2.70,P = 0.003)(RR = 1.44,P = 0.00756)。对于直径小于1mm的毛细血管扩张,LAS治疗明显优于POL治疗。对于直径大于1mm的毛细血管扩张,风险回归模型显示,与HS治疗相比,LAS的风险比为3.97(P = 0.047),POL的风险比为4.96(P = 0.486)。总之,下肢毛细血管扩张和网状静脉可以用Nd:YAG激光或硬化疗法成功治疗。建议用Nd:YAG激光治疗小的毛细血管扩张(直径小于1mm),而随着毛细血管扩张直径增大,聚多卡醇硬化疗法更有效。

相似文献

1
Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy.
Exp Ther Med. 2019 Feb;17(2):1106-1112. doi: 10.3892/etm.2018.6985. Epub 2018 Nov 16.
5
Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline.
Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23.
6
Sclerotherapy for leg telangiectasia--a blinded comparative trial of polidocanol and hypertonic saline.
Dermatol Surg. 1999 May;25(5):381-5; discussion 385-6. doi: 10.1046/j.1524-4725.1999.08263.x.
9
Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.
J Dermatol Surg Oncol. 1990 Sep;16(9):800-4. doi: 10.1111/j.1524-4725.1990.tb01563.x.
10
Long-pulsed 1064nm Nd:YAG laser in the treatment of leg veins: Systematic review.
Vascular. 2025 Feb;33(1):151-166. doi: 10.1177/17085381241236587. Epub 2024 Feb 27.

引用本文的文献

1
Brazilian guidelines on chronic venous disease of the Brazilian Society of Angiology and Vascular Surgery.
J Vasc Bras. 2023 Nov 6;22:e20230064. doi: 10.1590/1677-5449.202300642. eCollection 2023.
3
Treatment for telangiectasias and reticular veins.
Cochrane Database Syst Rev. 2021 Oct 12;10(10):CD012723. doi: 10.1002/14651858.CD012723.pub2.
4
Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.
Front Pharmacol. 2021 Jan 18;11:592654. doi: 10.3389/fphar.2020.592654. eCollection 2020.
6
The Second Conference of the Romanian Society of Immuno-Dermatology, Bucharest, September 27-29, 2018.
Exp Ther Med. 2019 Feb;17(2):979-981. doi: 10.3892/etm.2018.7067. Epub 2018 Dec 6.

本文引用的文献

2
Motor unit changes in normal aging: a brief review.
Rom J Morphol Embryol. 2014;55(4):1295-301.
3
How specific are venous symptoms for diagnosis of chronic venous disease?
Phlebology. 2014 Oct;29(9):580-6. doi: 10.1177/0268355513515859. Epub 2014 Jan 3.
5
European guidelines for sclerotherapy in chronic venous disorders.
Phlebology. 2014 Jul;29(6):338-54. doi: 10.1177/0268355513483280. Epub 2013 May 3.
6
[Foam sclerotherapy. Uses and indications in dermatology and phlebology].
Hautarzt. 2012 Jun;63(6):493-503; quiz 504-5. doi: 10.1007/s00105-012-2392-1.
8
Clinical and technical follow-up after sclerotherapy.
Dermatol Surg. 2010 Jun;36 Suppl 2:1004-9. doi: 10.1111/j.1524-4725.2009.01404.x.
9
The French polidocanol study on long-term side effects: a survey covering 3,357 patient years.
Dermatol Surg. 2010 Jun;36 Suppl 2:993-1003. doi: 10.1111/j.1524-4725.2009.01407.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验